Table 5.
Multivariable Cox regression for OS among MA patients with SPM
| Parameters | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|
| HR (95% CI) | P-value | HR (95% CI) | P-value | |
| Age at diagnosis | ||||
| ≤29 | 1 [Reference] | 1 [Reference] | ||
| 30–59 | 2.594 (2.049–3.282) | <0.001 | 2.241 (1.716–2.926) | <0.001 |
| ≥60 | 8.631 (6.74–11.052) | <0.001 | 4.494 (3.358–6.015) | <0.001 |
| Gender | ||||
| Female | 1 [Reference] | |||
| Male | 1.34 (1.169–1.537) | <0.001 | / | / |
| Race | ||||
| White | 1 [Reference] | 1 [Reference] | ||
| Black | 0.7 (0.518–0.946) | 0.02 | 0.627 (0.455–0.865) | 0.004 |
| Others | 0.776 (0.573–1.052) | 0.102 | 1.019 (0.747–1.391) | 0.904 |
| Marital status | ||||
| Married | 1 [Reference] | 1 [Reference] | ||
| Unmarried | 0.682 (0.59–0.787) | <0.001 | 1.358 (1.159–1.591) | <0.001 |
| Unknown | 0.792 (0.526–1.192) | 0.264 | 0.872 (0.576–1.318) | 0.515 |
| WHO grade | ||||
| Low-grade astrocytic tumors, Grade II | 1 [Reference] | 1 [Reference] | ||
| AA, Grade III | 1.817 (1.349–2.448) | <0.001 | 1.228 (0.861–1.751) | 0.257 |
| Glioblastoma, Grade IV | 5.312 (4.133–6.829) | <0.001 | 2.072 (1.54–2.787) | <0.001 |
| Unknown | 1.241 (0.95–1.62) | 0.113 | 1.033 (0.779–1.368) | 0.823 |
| Differentiated grade | ||||
| Grade I, well differentiated | 1 [Reference] | |||
| Grade II, moderately differentiated | 1.65 (1.126–2.42) | 0.01 | 1.524 (1.028–2.259) | 0.036 |
| Grade III, poorly differentiated | 2.879 (1.854–4.471) | <0.001 | 2.299 (1.444–3.658) | <0.001 |
| Grade IV, undifferentiated | 3.684 (2.569–5.282) | <0.001 | 2.176 (1.432–3.305) | <0.001 |
| Unknown | 3.623 (2.55–5.148) | <0.001 | 2.076 (1.403–3.071) | <0.001 |
| SEER stage | ||||
| Localized | 1 [Reference] | 1 [Reference] | ||
| Regional | 1.498 (1.159–1.936) | 0.002 | 1.284 (0.99–1.666) | 0.06 |
| Distant | 2.228 (0.922–5.385) | 0.075 | 2.192 (0.897–5.357) | 0.085 |
| Unknown | 0.569 (0.487–0.665) | <0.001 | 1.291 (1.091–1.527) | 0.003 |
| Surgery of first primary site | ||||
| Yes | 1 [Reference] | |||
| No | 1.028 (0.823–1.284) | 0.807 | / | / |
| Unknown | 0.559 (0.477–0.655) | <0.001 | / | / |
| Latency | ||||
| ≤11 months | 1 [Reference] | 1 [Reference] | ||
| 12–35 months | 0.354 (0.292–0.429) | <0.001 | 0.345 (0.282–0.422) | <0.001 |
| 36–59 months | 0.206 (0.162–0.261) | <0.001 | 0.197 (0.153–0.253) | <0.001 |
| 60–119 months | 0.105 (0.084–0.133) | <0.001 | 0.132 (0.103–0.169) | <0.001 |
| ≥120 months | 0.05 (0.039–0.063) | <0.001 | 0.063 (0.048–0.083) | <0.001 |
| Number of primary tumors | ||||
| 2 | 1 [Reference] | |||
| At least 3 | 0.773 (0.576–1.038) | 0.087 | / | / |